Nuvalent (NASDAQ:NUVL) is a clinical‐stage precision oncology company focused on the discovery and development of small molecule inhibitors for genetically defined cancers. Founded in 2019 and headquartered in Cambridge, Massachusetts, Nuvalent leverages a structure‐based drug design platform to address oncogenic targets that have proven difficult to inhibit with traditional therapies.
The company’s lead program targets the KRAS G12D mutation, one of the most prevalent oncogenic drivers in pancreatic, colorectal and other solid tumors, and is currently in early‐stage clinical evaluation. In parallel, Nuvalent is advancing additional candidate molecules against key drivers such as EGFR exon 20 insertion mutations and FGFR fusions, with the goal of offering new treatment options for patients with high unmet need.
Nuvalent’s discovery platform integrates covalent chemistry, high‐resolution structural analysis and proprietary screening methodologies to rapidly identify and optimize potent, selective compounds. Its research facility in Cambridge supports a multidisciplinary team of medicinal chemists, structural biologists and translational scientists working in close collaboration with clinical development experts.
James Sapirstein, co‐founder and Chief Executive Officer, leads the organization alongside a leadership team drawn from top biopharmaceutical companies and academic institutions. Under their stewardship, Nuvalent has established strategic collaborations and plans to initiate global clinical trials across North America and Europe, aiming to bring first‐in‐class precision medicines to cancer patients worldwide.
